Last update 25 Jan 2025

Universal allogeneic anti-CD19/BCMA CAR T-cells(Hematology Hospital of Chinese Academy of Medical Sciences)

Overview

Basic Info

Drug Type
Universal CAR-T
Synonyms-
Target
BCMA x CD19
Mechanism
BCMA modulators(B-cell maturation protein modulators), CD19 modulators(B-lymphocyte antigen CD19 modulators)
Therapeutic Areas
Immune System DiseasesHemic and Lymphatic DiseasesOther Diseases
Active Indication
Autoimmune Haemolytic Anaemias
Inactive Indication-
Originator Organization
Hematology Hospital of Chinese Academy of Medical Sciences
Active Organization
Hangzhou Xiniao Biotechnology Co., Ltd.Hematology Hospital of Chinese Academy of Medical Sciences
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Universal allogeneic anti-CD19/BCMA CAR T-cells(Hematology Hospital of Chinese Academy of Medical Sciences)
NCT06733610
/ RecruitingPhase 1IIT
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients with Autoimmune Hemolytic Anemia Have Failed ≥ 3 Lines of Therapy
100 Clinical Results associated with Universal allogeneic anti-CD19/BCMA CAR T-cells(Hematology Hospital of Chinese Academy of Medical Sciences)
Login to view more data
100 Translational Medicine associated with Universal allogeneic anti-CD19/BCMA CAR T-cells(Hematology Hospital of Chinese Academy of Medical Sciences)
Login to view more data
100 Patents (Medical) associated with Universal allogeneic anti-CD19/BCMA CAR T-cells(Hematology Hospital of Chinese Academy of Medical Sciences)
Login to view more data
100 Deals associated with Universal allogeneic anti-CD19/BCMA CAR T-cells(Hematology Hospital of Chinese Academy of Medical Sciences)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Autoimmune Haemolytic AnaemiasPhase 1
CN
Hangzhou Xiniao Biotechnology Co., Ltd.
05 Dec 2024
Autoimmune Haemolytic AnaemiasPhase 1
CN
Hematology Hospital of Chinese Academy of Medical Sciences
05 Dec 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free